Want to see EYPT full AI Analyst Report?
EyePoint Pharmaceuticals (EYPT) Income Statement
EyePoint Pharmaceuticals Income Statement
Last quarter (Q2 2026), EyePoint Pharmaceuticals's total revenue was $507.00K, a decrease of 90.49% from the same quarter last year. In Q2, EyePoint Pharmaceuticals's net income was $-94.47M. See EyePoint Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 31.37M | $ 43.27M | $ 46.02M | $ 41.40M | $ 36.94M | |
| $ 29.30M | $ 39.56M | $ 41.39M | $ 33.08M | $ 28.76M | |
| $ 272.74M | $ 185.41M | $ 116.45M | $ 132.72M | $ 84.04M | |
| Depreciation and Amortization | $ 2.31M | $ 1.54M | $ 464.00K | $ 2.45M | $ 2.77M |
| $ -229.34M | $ -129.23M | $ -69.00M | $ -96.62M | $ -50.15M | |
| $ -243.43M | $ -145.85M | $ -75.07M | $ -99.64M | $ -55.28M | |
| $ 11.75M | $ 15.07M | $ 4.36M | $ -2.62M | $ -3.14M | |
| $ -231.68M | $ -130.78M | $ -70.71M | $ -102.25M | $ -58.42M | |
| $ -231.96M | $ -130.87M | $ -70.80M | $ -102.25M | $ -58.42M | |
| Per Share Metrics | |||||
| Basic EPS | $ -3.17 | $ -2.32 | $ -1.82 | $ -2.74 | $ -2.03 |
| Diluted EPS | $ -3.17 | $ -2.32 | $ -1.82 | $ -2.74 | $ -2.03 |
| Weighted Average Shares Outstanding | 73.25M | 56.30M | 38.90M | 37.32M | 28.76M |
| Weighted Average Shares Outstanding (Diluted) | 73.25M | 56.30M | 38.90M | 37.32M | 28.76M |
Currency in USD